Seeking Alpha: aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise ... aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market.
Efzofitimod aims to modulate inflammation without immune ... News Medical: Methotrexate found to be effective alternative to prednisone for pulmonary sarcoidosis Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ... Nasdaq: aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Nasdaq: ATyr Pharma Advances Pulmonary Sarcoidosis Treatment With Efzofitimod At ATS 2025 EurekAlert!: COVID-19 infection and pulmonary sarcoidosis: a systematic review and meta-analysis of morbidity, severity and mortality COVID-19 infection and pulmonary sarcoidosis: a systematic review and meta-analysis of morbidity, severity and mortality Business Wire: Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
